Intra-arterial tenecteplase during thrombectomy for acute stroke (BRETIS-TNK II) : rationale and design
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: Our recent pilot study suggests intra-arterial tenecteplase (TNK) during the first pass of endovascular treatment (EVT) seems safe, may increase first-pass reperfusion and good outcome in acute ischaemic stroke (AIS) patients with large-vessel occlusion (LVO).
AIMS: To determine the efficacy and safety of intra-arterial TNK administration during EVT in AIS-LVO patients presenting up to 24 hours from symptom onset.
SAMPLE SIZE ESTIMATES: A maximum of 380 patients are required to test the superiority hypothesis with 80% power according to a two-side 0.05 level of significance, stratified by age, gender, baseline systolic blood pressure, prestroke modified Rankin Scale (mRS), baseline National Institute of Health stroke scale, baseline ASPECTS, time from onset to groin puncture, intravenous thrombolysis before EVT, stroke territory and stroke aetiology.
DESIGN: Intra-arterial TNK during thrombectomy for acute stroke (BRETIS-TNK II) study is a prospective, randomised, adaptive enrichment, open-label, blinded end point, multicentre study. Eligible AIS-LVO patients are randomly assigned into the experimental group and control group with a ratio of 1:1. The experimental group will be treated with intra-arterial infusion of TNK during EVT. The control group will be treated with standard EVT.
OUTCOME: The primary end point is a favourable outcome, defined as an mRS score of 0-2 at 90 days. The primary safety end point is symptomatic intracranial haemorrhage within 48 hours, which is defined as an increase in the National Institutes of Health Stroke Scale score of ≥4 points as a result of the intracranial haemorrhage.
CONCLUSIONS: The results of BRETIS-TNK II will provide evidence for the efficacy and safety of intra-arterial TNK administration during EVT in AIS patients with LVO.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Stroke and vascular neurology - 9(2024), 1 vom: 27. Feb., Seite 59-65 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Zi-Ai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.4.21.68 |
|---|
| Anmerkungen: |
Date Completed 29.02.2024 Date Revised 27.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/svn-2023-002377 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356722783 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356722783 | ||
| 003 | DE-627 | ||
| 005 | 20240327235137.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/svn-2023-002377 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1350.xml |
| 035 | |a (DE-627)NLM356722783 | ||
| 035 | |a (NLM)37169399 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Zi-Ai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intra-arterial tenecteplase during thrombectomy for acute stroke (BRETIS-TNK II) |b rationale and design |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.02.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND: Our recent pilot study suggests intra-arterial tenecteplase (TNK) during the first pass of endovascular treatment (EVT) seems safe, may increase first-pass reperfusion and good outcome in acute ischaemic stroke (AIS) patients with large-vessel occlusion (LVO) | ||
| 520 | |a AIMS: To determine the efficacy and safety of intra-arterial TNK administration during EVT in AIS-LVO patients presenting up to 24 hours from symptom onset | ||
| 520 | |a SAMPLE SIZE ESTIMATES: A maximum of 380 patients are required to test the superiority hypothesis with 80% power according to a two-side 0.05 level of significance, stratified by age, gender, baseline systolic blood pressure, prestroke modified Rankin Scale (mRS), baseline National Institute of Health stroke scale, baseline ASPECTS, time from onset to groin puncture, intravenous thrombolysis before EVT, stroke territory and stroke aetiology | ||
| 520 | |a DESIGN: Intra-arterial TNK during thrombectomy for acute stroke (BRETIS-TNK II) study is a prospective, randomised, adaptive enrichment, open-label, blinded end point, multicentre study. Eligible AIS-LVO patients are randomly assigned into the experimental group and control group with a ratio of 1:1. The experimental group will be treated with intra-arterial infusion of TNK during EVT. The control group will be treated with standard EVT | ||
| 520 | |a OUTCOME: The primary end point is a favourable outcome, defined as an mRS score of 0-2 at 90 days. The primary safety end point is symptomatic intracranial haemorrhage within 48 hours, which is defined as an increase in the National Institutes of Health Stroke Scale score of ≥4 points as a result of the intracranial haemorrhage | ||
| 520 | |a CONCLUSIONS: The results of BRETIS-TNK II will provide evidence for the efficacy and safety of intra-arterial TNK administration during EVT in AIS patients with LVO | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Stroke | |
| 650 | 4 | |a Thrombectomy | |
| 650 | 7 | |a Tenecteplase |2 NLM | |
| 650 | 7 | |a WGD229O42W |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Qiu, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Thanh |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shouchun |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Huaizhang |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Di |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hui-Sheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stroke and vascular neurology |d 2016 |g 9(2024), 1 vom: 27. Feb., Seite 59-65 |w (DE-627)NLM263633950 |x 2059-8696 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:1 |g day:27 |g month:02 |g pages:59-65 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/svn-2023-002377 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 1 |b 27 |c 02 |h 59-65 | ||